BofA and JPMorgan Lower Tempus AI, Inc. (TEM) Price Targets on Valuation Concerns

We recently compiled a list of the 7 Most Promising Gene Editing Stocks According to Analysts. Tempus AI, Inc. stands third on our list among the most promising stocks.

TheFly reported on December 15 that BofA Securities analyst Michael Ryskin lowered his price target on TEM to $80 from $90 while maintaining a Neutral rating, reflecting valuation considerations after the rally.

On the same day, JPMorgan analyst Casey Woodring also reduced his price target to $80 from $85, reiterating a Neutral outlook as he assessed the company’s growth prospects against its current share price.

These target revisions came despite continued operational momentum at TEM. The company announced that ten scientific abstracts were accepted for presentation at the 2025 San Antonio Breast Cancer Symposium, which took place from December 9 to December 12, 2025. The abstracts highlighted research utilizing the company’s multimodal data platform to support cancer research and clinical insights, underscoring the business’s expanding role in precision medicine.

Tempus AI, Inc. (NASDAQ:TEM) is a healthcare technology company that applies artificial intelligence (AI) to precision medicine, focusing on genomic sequencing, diagnostic testing, and data analysis to help physicians personalize treatment decisions, especially in oncology.

While we acknowledge the potential of TEM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy NOW 

Disclosure: None.